Shots:

• The two companies collaborated to jointly conduct P-II study combining BNT111 FixVac and Libtayo in patients with anti-PD1-refractory/relapsed- unresectable Stage III or IV cutaneous melanoma with the expected initiation of the study in Q4’20
• The companies will equally share the development costs for the clinical trial and will contribute their products for the trial. Each party will retain full commercial rights for its respective product and record revenues related to its own product
• Additionally- the companies plan to pursue a clinical trial for the combination in a 2L setting for advanced melanoma. The combination therapy has the potential to augment the immune system’s ability to effectively recognize melanoma in multiple ways and to improve immune to control the cancer

­ Ref: GlobeNewswire | Image: OrthoSpine News